Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry.

Abstract

AIMS:

To determine the characteristics of patients with coronary artery disease (CAD), peripheral artery disease (PAD), or both, initiating dual pathway inhibition (DPI) using rivaroxaban 2.5 mg twice daily plus aspirin, and to report their clinical outcomes and bleeding rates in clinical practice compared to the COMPASS randomized trial, which provided the basis for using DPI in this patient population.

METHODS AND RESULTS:

XATOA is a prospective registry of 5532 patients: of which, 72.7% had CAD, 58.9% had PAD, and 31.6% had both. The mean age of patients was 68 years and 25.5% were women. The mean follow-up period was 15 months. The most frequently reported reason for initiating DPI was the presence of existing, worsening or newly diagnosed risk characteristics (n = 4753, 85.9%). Before initiating DPI, 75.3% received a single antiplatelet and 18.3% received various antiplatelet combinations. The incidence of major adverse cardiovascular events (MACE), major adverse limb events (MALE) and acute or severe limb ischaemia was 2.26, 3.57, and 1.54 per 100 patient-years, respectively, among the 5532 patients in XATOA. Corresponding rates in COMPASS were 2.18, 0.19, and 0.12 per 100 patient-years, respectively. Major bleeding rates were 0.95 and 1.67 per 100 patient-years in XATOA and COMPASS, respectively.

CONCLUSION:

High-risk vascular patients are prioritized for DPI in clinical practice, and rates of MACE are similar to COMPASS, but MALE rates are higher in XATOA, consistent with the greater proportion of PAD patients. Major bleeding rates were lower in XATOA. The findings provide support for favourable net clinical benefit of DPI in high-risk vascular patients.

ONE-SENTENCE SUMMARY:

The characteristics of patients initiated on dual pathway inhibition (DPI: rivaroxaban 2.5  mg twice daily plus aspirin) have not previously been defined in clinical practice and the XATOA registry findings demonstrate patient outcomes are consistent with those of the COMPASS trial, despite geographic differences in recruitment and the higher proportion of PAD patients.

• Authors: Keith A A Fox, Victor Aboyans, E Sebastian Debus, Uwe Zeymer, Martin R Cowie, Manesh Patel, Robert C Welsh, Jackie Bosch, Alain Gay, Kai Vogtländer, Sonia S Anand
• Journal: European heart journal. Cardiovascular pharmacotherapy (Eur Heart J Cardiovasc Pharmacother) Vol. 8 Issue 8 Pg. 825-836 (12 02 2022) ISSN: 2055-6845 [Electronic] England
• PMID: 35594542 (Publication Type: Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

Chemical References

• Rivaroxaban
• Factor Xa Inhibitors
• Aspirin

Topics

• Humans
• Female
• Aged
• Male
• Rivaroxaban (adverse effects)
• Factor Xa Inhibitors (adverse effects)
• Aspirin (adverse effects)
• Peripheral Arterial Disease (diagnosis, drug therapy, epidemiology)
• Registries
• Coronary Artery Disease (diagnosis, drug therapy, epidemiology)
• Hemorrhage (chemically induced)